A new drug for the treatment of Parkinson's disease psychosis:pimavanserin
SONG Pin-rao
WEN Li-min
JIANG Feng
LI Di
LIN Bin-bin
CAO Li-ping
Abstract：Pimavanserin is a highly selective oral serotonin 5-HT2A inverse agonist.It was firstly approved for the treatment of hallucinations and delusions in the setting of Parkinson's disease psychosis(PDP) by U.S.Food and Drug Administration in April,2016.In this paper,the mechanism of action,pharmacokinetic profiles,clinical studies,as well as drug interactions of pimavanserin were reviewed.
Keywords：pimavanserinParkinson's disease psychosis5-HT2A inverse agonistclinical studies
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：3( 481-483 )